Introduction
Most HIV1-infected patients initiating HAART (combined antiretroviral therapy, cART) experience an effective control of HIV replication in plasma associated with an increase of CD4 þ T-cell numbers [1] . However, many of them fail to restore CD4 þ T-cell counts above 500 cells/ml and/or a CD4 þ : CD8 þ ratio ! 1. This is partly due to persistent immune activation and inflammation, driven by residual HIV replication, microbial translocation and chronic viral infections [2] such as hepatitis C virus (HCV) infection, which concerns around 15-30% of HIV-infected patients in central Europe [3] .
Chronic HCV-infection is associated with CD8 þ T-cell dysfunction, ineffective viral control [4, 5] and promotion of T-cell exhaustion and senescence [6] . Such abnormalities are enhanced during HIV infection. Therefore, HCV coinfection may interfere with immune restoration in HIV-infected patients achieving long-term HIV suppression.
This study aimed to determine the impact of HCV coinfection on longitudinal changes in CD4 þ and CD8 þ T-cell counts in HIV-infected patients under cART who achieved a sustained undetectable plasma HIV viral load (HIV-pVL) for at least 3 years. In order to focus on the actual effect of HCV infection on immune reconstitution, we analysed data collected from HIV/HCV-coinfected patients who were naive of HCV-targeted treatment.
Materials and methods

Study design and procedures
This is a retrospective observational study conducted by the Clinical Research Department of the Immuno-Hematological clinical unit-Centre d'Information et Soins de l'Immunodéficience Humaine (CISIH) et des hepatites virales of the Sainte Marguerite -Marseille South Hospital. Data of patients under cART who achieved undetectable HIV-pVL for at least 3 years were collected from our electronic database, NADIS (Fedialis Medica, Marly le Roi, France) [7, 8] from January 1997 to April 2005. This period was defined in order to select patients who were naive of interferon (IFN)-based hepatitis treatment. HCV coinfection was identified on the basis of HCV-positive serology. Splenectomized patients and patients who have received a course of IFN-a or IFN-b prior to or during the study period were excluded. The characteristics of patients were described at the time of initiation of the long-term inhibitor antiretroviral treatment (LTIT) and at the first undetectable HIV-pVL (baseline). Dynamic of T-cell compartments (CD4 þ and CD8 þ T-cell counts and percentages) were assessed at baseline and every 6 months during the followup. Sex, age, duration of HIV follow-up, transmission risk group, Centers for Disease Control and Prevention (CDC) stage, hepatitis B coinfection (positive hepatitis B surface antigen), duration of cART exposure and cART regimen [nucleoside reverse transcriptase inhibitor (NRTI)-based, nonnucleoside/NRTI (NNRTI)-based, protease inhibitor based] were analysed. For T-cell immunophenotyping, EDTA fresh whole blood (100 ml) was incubated with combinations of fluorochrome-conjugated mAbs specific for CD3 þ , CD4 þ and CD8 þ (Beckman Coulter, Brea, California, USA) and the analysis was performed using an FC500 cytometer (Beckman Coulter). HCV-RNA was detected and/or quantified by real-time PCR assays using COBAS TaqMan 
Results
Demographic and clinical characteristics of patients
Out of the 1495 HIV-infected patients registered in our database during the study period, 356 fulfilled the selection criteria, of whom 226 were HIV mono-infected (group 1) and 130 were HCV coinfected (group 2). Patients' characteristics are reported in Table 1 . Patients in the two groups were mostly men (66.8 and 76.2% for group 1 and 2, respectively) and differed in age (lower in group 1), HIV transmission risk group (mostly through intravenous drug use in group 2), CDC stage C (higher in group 1) and duration of HIV follow-up, which was longer in group 2 (10 [6-12] vs. 4 [1-8] years, P < 0.001). Regardless of HCV status, most patients were receiving a triple combination of antiretroviral drugs at baseline. LTIT regimens were comparable between groups, with the most frequent regimens being two NRTIs and one protease inhibitor (50%), three NRTIs (14.9%) and then two NRTIs and one NNRTI (12.8%).
Regarding HCV infection, 55 patients (42.3%) were HCV-genotype 1 coinfected (G1), 34 (26.1%) with HCV-genotype 3 (G3), 14 (11.8%) with HCV-genotype 4 (G4), and genotype was not available for 27 (20.8%) patients. Qualitative HCV-RNA data were available for 88 patients (67.7%), of whom 76 were positive (86%), and only nine quantitative HCV-RNA assessments were available at baseline (median HCV viral load ¼ 5.7 log UI/ml). Median CD8 þ T-cell counts were higher in group 2, although under significance threshold. Median CD4 þ : CD8 þ ratio at baseline was comparable between the groups; however, the proportion of patients with a CD4 þ : CD8 þ ratio at least 1 was significantly higher in group 1 (11.4 vs. 1.6% in group 1 and 2, respectively, P ¼ 0.001).
Evolution of CD4 R T cells, CD8 R T cells and the CD4 R : CD8 R ratio During 3 years of follow-up starting from the first undetectable HIV-pVL, mean and median CD4 þ T-cell counts increased significantly regardless of HCV status ( Fig. 1a and Supplementary Table 1 , http://links.lww. com/QAD/A676, respectively), although mean CD4 þ cell percentage increased significantly in group 1 only ( Fig. 1a ). In contrast, median CD8 þ counts decreased significantly only in group 1 (Supplementary Table 1 , http://links.lww.com/QAD/A676). More strikingly, patients from group 2 displayed higher mean CD8 þ counts than group 1 at all times but 18 months ( Fig. 1a ; mean diff. ¼ 135.71 AE 26.89 cells/ml, P < 0.001). A higher mean CD8 þ cell percentage under significance threshold was also observed in group 2 than group 1 (mean diff. ¼ 2.427 AE 0.572%, P ¼ 0.12). A similar pattern of CD8 þ evolution was observed when focusing on patients with detectable HCV-RNA ( Supplementary  Fig. 1 , http://links.lww.com/QAD/A676). Mean CD4 þ : CD8 þ ratio as well as the proportion of patients with CD4 þ : CD8 þ ratio ! 1 remained significantly higher in HIV monoinfected patients all through the follow-up (Fig. 1b) .
Impact of hepatitis C virus genotype on CD8 R T-cell dynamics
Analysis of the evolution of CD4 þ and CD8 þ T-cell counts according to HCV genotype showed that HCV-G1 coinfected patients displayed higher CD8 þ counts at all times but 18 months, without significant HCV supports CD8 R expansion on cART Zaegel-Faucher et al. 1507 variation throughout the study period (Fig. 1c ). No significant differences were observed between HCV-G1 subtype 1a (n ¼ 44) and 1b (n ¼ 11) (data not shown). HCV-G3 coinfected patients presented mean CD8 þ values comparable to group 1 at baseline, which became higher than group 1 after 24 months. In contrast, for HCV-G4 coinfected patients, mean CD8 þ counts steadily dropped from baseline and became comparable to the group 1 after 3 years.
Factors associated with CD8 R T-cell rates and hepatitis C virus infection
We performed bivariate Pearson's analysis in order to identify variables among the clinical/demographic characteristics of our cohort that were correlated to CD8 þ counts at baseline, to CD8 þ counts after 3 years of HIV suppression on cART or to HCV-positive serology. The results of this analysis are summarized in the Supplementary Table 2 , http://links.lww.com/QAD/ A676. On this basis, we identified baseline CD4 þ : CD8 þ ratio, CD4 þ and CD8 þ cell counts at baseline, sex, age and the duration of HIV follow-up as potential confounding factors. Therefore, we performed multivariate linear regression analysis adjusting by these variables, which corroborated the correlation between HCV-positive serology and CD8 þ cell counts after 3 years of HIV suppression (coeff. to HIV/HCV-coinfected patients with a positive HCV-PCR record (HCV coinfection 3 yrs : coeff ¼ 0.212, P ¼ 0.006; Supplementary Figure 1 , http://links.lww. com/QAD/A676).
Discussion
This study demonstrates that in spite of long-term sustained undetectable HIV-pVL and concomitant CD4 þ reconstitution on cART, HCV coinfection supports an expansion of the CD8 þ T-cell compartment, which results in a poorer restoration of the CD4 þ : CD8 þ ratio than HIV mono-infected patients.
An expansion of CD8 þ T cells was previously reported in studies involving smaller cohorts of HIV/HCV-coinfected patients [9] [10] [11] . However, the number/heterogeneity of the individuals regarding HIV status and/or previous hepatitis treatment in these studies did not allow drawing conclusions about this immune condition. Our selection of HIV/HCV seropositive patients among HIV suppressors on cART followed between 1997 and 2005 provides a homogeneous cohort of naive HIV/HCVinfected patients for which an eventual contribution of HIV on CD8 þ amplification can be ruled out. Although only a small number of these patients had a documented HCV-RNA status, results from HCV-RNA positive patients were consistent with those from the whole HCV sero-positive cohort. Hence, our results allow clear conclusions to be made regarding the enhanced expansion of the CD8 þ compartment related to HCV coinfection.
cART-induced HIV suppression is expected to trigger immune restoration. However, we observed that untreated HCV coinfection was paralleled by a lower CD4 þ : CD8 þ ratio and a smaller proportion of coinfected patients achieving CD4 þ : CD8 þ ratio ! 1 after 3 years of HIV suppression on cART. This is of clinical relevance, as recent studies demonstrated that the failure to normalize CD4 þ : CD8 þ ratio under cART increases the risk of incidence of non-AIDS related events, even when CD4 þ cell counts are restored (>500 cells/ml) [12, 13] .
HCV-specific CD8 þ T cells from HIV-infected patients were shown to be less efficient at clearing infection than their HIV-free counterparts [14] . This paradox of expansion and dysfunction of CD8 þ T cells may be explained by the fact that chronic HCV infection may favour the continual expansion of short-lived cells, while dampening the regeneration of ready-to-kill long-lived ones. This situation was reported in naive HIV-infected patients, for whom persistent HIV replication was associated with accelerated CD8 þ T-cell turnover [15] , which normalized on cART [16] .
An impaired CD4 þ recovery was previously reported in HIV/HCV-G3 coinfected patients after a year of HIV suppression [17] . In our study, we found a greater expansion of the CD8 þ compartment in HIV/HCV-G1 and HCV-G3 coinfected patients, with no significant impact on CD4 þ restoration. To our knowledge, this is the first report of such an impact of HCV genotype on CD8 þ T-cell compartment regulation.
HCV mono-infected patients are known to harbour a high level of exhausted HCV-specific CD8 þ T cells [6] , which also seems to be higher in HIV/HCV-coinfected patients as recently reported [5] . The retrospective design of our study did not allow performing further immunophenotyping analysis to document the nature (activated, memory, exhausted) of CD8 þ T cells amplified during HCV coinfection. Unfortunately, quantitative data on HCV-RNA were available for only a few patients, which made it impossible to estimate the impact of HCV viral load on CD8 þ T-cell regulation.
As inflammation fosters the most severe comorbidities of HIV, our results are supportive of initiating HCV treatment in HIV/HCV-coinfected patients regardless of fibrosis score. Preliminary data supporting this viewpoint were provided recently in a study of eight acute HCV-infected patients receiving PEG-IFN/RBV displaying a reduction in CD8 þ responses [18] .
